keyword
MENU ▼
Read by QxMD icon Read
search

Neuroendocrine, liver

keyword
https://www.readbyqxmd.com/read/29158141/patient-reported-tolerance-in-treatments-approved-in-neuroendocrine-tumors-a-national-survey-from-the-french-group-of-endocrine-tumors
#1
Arnaud Plante, Eric Baudin, Christine Do Cao, Olivia Hentic, Olivier Dubreuil, Eric Terrebonne, Victoire Granger, Denis Smith, Catherine Lombard-Bohas, Thomas Walter
BACKGROUND: Patients with advanced neuroendocrine tumors (NETs) benefit from an increasing number of treatments. The patient's preference could help physicians to choose among these options. Our patient-reported survey aims to compare the perceived tolerance of NETs treatments. METHODS: Patients treated by at least three different therapeutic options have evaluated their perceived tolerance from one (very good) to five (very poor) for each single treatment. Referent physician confirmed the type and ranking over time of each treatment...
November 17, 2017: Clinics and Research in Hepatology and Gastroenterology
https://www.readbyqxmd.com/read/29154080/changes-in-gene-expression-in-small-bowel-neuroendocrine-tumors-associated-with-progression-to-metastases
#2
Kendall J Keck, Patrick Breheny, Terry A Braun, Benjamin Darbro, Guiying Li, Joseph S Dillon, Andrew M Bellizzi, Thomas M O'Dorisio, James R Howe
BACKGROUND: Small bowel neuroendocrine tumors (SBNETs) present frequently with metastases, yet little is known about the molecular basis of this progression. This study sought to identify the serial differential expression of genes between normal small bowel, primary small bowel neuroendocrine tumors, and liver metastases. METHODS: RNA isolated from matched normal small bowel tissue, primary small bowel neuroendocrine tumors, and liver metastases in 12 patients was analyzed with whole transcriptome expression microarrays and RNA-Seq...
November 16, 2017: Surgery
https://www.readbyqxmd.com/read/29152667/correction-to-peptide-receptor-radionuclide-therapy-prrt-in-european-neuroendocrine-tumour-society-enets-grade-3-g3-neuroendocrine-neoplasia-nen-a-single-institution-retrospective-analysis
#3
Sue Ping Thang, Mei Sim Lung, Grace Kong, Michael S Hofman, Jason Callahan, Michael Michael, Rodney J Hicks
On page 4 of the original version of this article, the text "Eight (29%) of the patients had significant FDG-avid disease (i.e. with intensity above liver parenchyma) prior to treatment" needs to be corrected.
November 20, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29151522/a-case-of-large-cell-neuroendocrine-carcinoma-harboring-an-alk-rearrangement-with-response-to-alectinib
#4
Nobuyoshi Hayashi, Akihisa Fujita, Toyohiro Saikai, Hirotugu Takabatake, Mie Sotoshiro, Kyuutarou Sekine, Akihiko Kawana
Anaplastic lymphoma kinase (ALK) rearrangement is most commonly observed in lung adenocarcinoma in a subset of lung cancer. Large-cell neuroendocrine carcinoma (LCNEC) harboring an ALK rearrangement is very rare. Based on the findings from a transbronchial lung biopsy, a 75-year-old non-smoking woman was diagnosed with LCNEC with multiple liver and bone metastases. After seven cycles of cytotoxic chemotherapy, her genotype testing demonstrated ALK rearrangement. Subsequently, she was administered alectinib and exhibited a partial response...
November 20, 2017: Internal Medicine
https://www.readbyqxmd.com/read/29145267/osteoblastic-bone-metastases-from-neuroendocrine-tumor-net-of-unknown-origin-detected-by-18fluorocholine-pet-ct-and-its-comparison-with-68gallium-dotatoc-pet-ct-case-report-and-review-of-the-literature
#5
Alberto Bongiovanni, Federica Recine, Monica Celli, Giulia Marcantognini, Flavia Foca, Chiara Liverani, Valentina Fausti, Alessandro De Vita, Giacomo Miserocchi, Laura Mercatali, Dino Amadori, Toni Ibrahim
RATIONALE: Choline (CH) positron emission tomography (PET)/computed tomography (CT) with fluorine 18 (F) CH is increasingly used not only to evaluate patients with biochemically recurrent prostate cancer but also to assess metastatic lesions that are difficult or impossible to identify using more conventional modalities. Our experience with CH PET/CT has shown that it can also be used for many other malignancies. PRESENTING CONCERNS: A 71-year-old male with a neuroendocrine tumor (NET) of unknown origin showed osteoblastic bone metastases positive to F-CH PET...
November 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29143892/update-in-the-therapy-of-advanced-neuroendocrine-tumors
#6
REVIEW
Inbal Uri, Shani Avniel-Polak, David J Gross, Simona Grozinsky-Glasberg
Neuroendocrine tumors (NETs) are rare neoplasms, with an estimated annual incidence of ~ 6.9/100,000. NETs arise throughout the body from cells of the diffuse endocrine system. More than half originate from endocrine cells of the gastrointestinal tract and the pancreas, thus being referred to as gastroenteropancreatic NETs (GEP-NETs). The only treatment that offers a cure is surgery; however, most patients are diagnosed with metastatic disease, and curative surgery is usually not an option. These patients can be offered long-term systemic treatment, for both symptomatic relief and tumor growth suppression...
November 16, 2017: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/29142475/predictive-factors-associated-with-carcinoid-syndrome-in-patients-with-gastrointestinal-neuroendocrine-tumors
#7
Beilei Cai, Michael S Broder, Eunice Chang, Tingjian Yan, David C Metz
AIM: To discover unknown factors associated with carcinoid syndrome (CS) with the goal of earlier diagnosis of CS. METHODS: In this retrospective case-control study using United States administrative claims, patients (≥ 18 years) newly-diagnosed with gastrointestinal neuroendocrine tumors (GI NETs) without CS (controls) were exactly matched to patients with CS (cases) based on NET diagnosis date at a 3-to-1 ratio. Study index date was first CS diagnosis (controls: same distance from NET diagnosis as cases)...
October 28, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/29136022/prognostic-significance-of-cytokeratin-19-expression-in-pancreatic-neuroendocrine-tumor-a-meta-analysis
#8
Dong Cen, Jiang Chen, Zheyong Li, Jie Zhao, Xiujun Cai
BACKGROUND: Pancreatic neuroendocrine tumor (PNET) comprises 1-2% of all pancreatic tumors, but its incidence is increasing. Although many studies have investigated the correlation between cytokeratin 19 (CK-19) and PNET, the prognostic significance of CK-19 expression in PNET is inconclusive. METHODS: Eligible studies were retrieved from Pubmed, Elsevier, Embase, Cochrane Library and Web of Science databases. All relevant data were extracted to analyze the relationship between CK-19 and PNET...
2017: PloS One
https://www.readbyqxmd.com/read/29132721/endocrine-pathology-past-present-and-future
#9
REVIEW
Sylvia L Asa, Ozgur Mete
Endocrine pathology is the subspecialty of diagnostic pathology which deals with the diagnosis and characterisation of neoplastic and non-neoplastic diseases of the endocrine system. This relatively young subspecialty was initially focused mainly on thyroid and parathyroid pathology, with some participants also involved in studies of the pituitary, the endocrine pancreas, and the adrenal glands. However, the endocrine system involves much more than these traditional endocrine organs and the discipline has grown to encompass lesions of the dispersed neuroendocrine cells, including neuroendocrine tumours (NETs) of the lungs, gastrointestinal tract, thymus, breast and prostate, as well as paraganglia throughout the body, not just in the adrenals...
November 10, 2017: Pathology
https://www.readbyqxmd.com/read/29127554/is-there-any-role-for-minimally-invasive-surgery-in-net
#10
REVIEW
M Thomaschewski, H Neeff, T Keck, H P H Neumann, T Strate, E von Dobschuetz
Neuroendocrine tumors (NET) represent the variability of almost benign lesions either secreting hormones occurring as a single lesion up to malignant lesions with metastatic potential. Treatment of NET is usually performed by surgical resection. Due to the rarity of NET, surgical treatment is mainly based on the experience and recommendations of experts and less on the basis of prospective randomized studies. In addition, the development and establishment of new surgical procedures is made more difficult by their rarity...
November 11, 2017: Reviews in Endocrine & Metabolic Disorders
https://www.readbyqxmd.com/read/29120653/-thyroid-carcinomas-the-present-view-on-diagnostics-and-therapy
#11
Petr Vlček, Dana Nováková, Rami Katra
Thyroid carcinoma (TC) represents 1-2 % of all human tumors, and is the seventh most common tumor. Women are in large majority among new patients. For women, this is the fifth most common tumor. In the Czech Republic, 1 143 new cases of TC were diagnosed in 2015. It is the tumor with the highest increase in incidence. Among newly diagnosed tumors, most of those are differentiated thyroid gland carcinomas (DTCs) originating from follicular thyroid cells. These tumors are follicular and papillary carcinomas and Hurthle carcinoma, accounting for 95 % of new cases...
2017: Vnitr̆ní Lékar̆ství
https://www.readbyqxmd.com/read/29116540/long-term-safety-of-long-acting-octreotide-in-patients-with-diabetic-retinopathy-results-of-pooled-data-from-2-randomized-double-blind-placebo-controlled-phase-3-studies
#12
Rosario Pivonello, Giovanna Muscogiuri, Geoffrey Holder, Michaela Paul, Severine Sarp, Anastasia Lesogor, Pierre Jordaan, Johannes Eisinger, Annamaria Colao
PURPOSE: Octreotide (OCT) has been successfully used for treatment of acromegaly and neuroendocrine tumors for more than 30 years. However, long-term safety of OCT has not been documented in placebo-controlled setting. This present analysis pooled safety data from two similarly-designed, randomized, and placebo-controlled studies to evaluate long-term safety of long-acting OCT (20, 30 mg); targeted post-hoc analyzes focused on cardiac, hepatic, and renal safety. METHODS: Two studies (NCT00131144, NCT001308450) were conducted in patients with diabetic retinopathy (OCT20 = 191, OCT30 = 348, placebo = 347)...
November 7, 2017: Endocrine
https://www.readbyqxmd.com/read/29112739/organophosphate-flame-retardants-alter-adult-mouse-homeostasis-and-gene-expression-in-a-sex-dependent-manner-potentially-through-interactions-with-er%C3%AE
#13
Elizabeth A Krumm, Vipa J Patel, Taylor S Tillery, Ali Yasrebi, Jianliang Shen, Grace L Guo, Stephanie M Marco, Brian T Buckley, Troy A Roepke
Flame retardants (FR) such as polybrominated diphenyl ethers (PBDE) and organophosphate FR (OPFR) persist in the environment and interact with multiple nuclear receptors involved in homeostasis, including estrogen receptors (ER). However, little is known about the effects of FR, especially OPFR, on mammalian neuroendocrine functions. Therefore, we investigated if exposure to FR alters hypothalamic gene expression and whole-animal physiology in adult wild-type (WT) and ERα KO mice. Intact WT and KO males and ovariectomized WT and KO females were orally dosed daily with vehicle (oil), 17α-ethynylestradiol (2...
November 3, 2017: Toxicological Sciences: An Official Journal of the Society of Toxicology
https://www.readbyqxmd.com/read/29108359/surgical-resection-of-primary-tumor-improves-survival-of-pancreatic-neuroendocrine-tumor-with-liver-metastases
#14
Lianyuan Tao, Dianrong Xiu, Abuduhaibaier Sadula, Chen Ye, Qing Chen, Hanyan Wang, Zhipeng Zhang, Lingfu Zhang, Ming Tao, Chunhui Yuan
This study investigates survival of patients diagnosed with pancreatic neuroendocrine tumor with liver metastases based on local treatment on the primary tumor. Patients diagnosed with stage IV PNET between 2010 and 2014 were identified from the Surveillance Epidemiology and End Results database. Cancer-Specific Survival and Overall Survival were examined. A total of 191 patients with pancreatic neuroendocrine tumor with liver metastases were included in this analysis. There were 47 patients (24.6%) who received surgical resection and 144 (75...
October 3, 2017: Oncotarget
https://www.readbyqxmd.com/read/29107992/software-assisted-dosimetry-in-peptide-receptor-radionuclide-therapy-with-177lutetium-dotatate-for-various-imaging-scenarios
#15
Dennis Kupitz, Christoph Wetz, Heiko Wissel, Florian Wedel, Ivayla Apostolova, Thekla Wallbaum, Jens Ricke, Holger Amthauer, Oliver S Grosser
In peptide receptor radionuclide therapy (PRRT) of patients with neuroendocrine neoplasias (NENs), intratherapeutic dosimetry is mandatory for organs at risk (e.g. kidneys) and tumours. We evaluated commercial dosimetry software (Dosimetry Toolkit) using varying imaging scenarios, based on planar and/or tomographic data, regarding the differences in calculated organ/tumour doses and the use for clinical routines. A total of 16 consecutive patients with NENs treated by PRRT with 177Lu-DOTATATE were retrospectively analysed...
2017: PloS One
https://www.readbyqxmd.com/read/29104610/functional-pancreatic-neuroendocrine-tumour-causing-cushing-s-syndrome-the-effect-of-chemotherapy-on-clinical-symptoms
#16
Paulo Henrique do Amor Divino, Katia Regina Marchetti, Madson Q Almeida, Rachel P Riechelmann
Background: Neuroendocrine tumours (NETs) are a heterogeneous group of diseases that can originate from any part of the gastrointestinal tract, bronchi, thyroid and pancreas. These tumours may be functioning or not depending on their ability to produce active substances, such as adrenocorticotrophic hormone (ACTH). ACTH-producing pancreatic neuroendocrine tumours are rare, with limited data about effective antitumor therapies. Case Report: A 58-year-old man with a history of type-2 diabetes mellitus and arterial hypertension was diagnosed with Cushing's syndrome (CS) secondary to an ACTH ectopic production from a well-differentiated neuroendocrine tumour of the pancreas metastatic to the liver...
2017: Ecancermedicalscience
https://www.readbyqxmd.com/read/29103839/can-echogenic-appearance-of-neuroendocrine-liver-metastases-on-intraoperative-ultrasonography-predict-tumor-biology-and-prognosis
#17
Epameinondas Dogeas, Charing C N Chong, Matthew J Weiss, Nita Ahuja, Michael A Choti
BACKGROUND: Determining the biologic behavior of neuroendocrine liver metastases (NELM) is important when managing patients with this disease. We sought to define the intraoperative ultrasound (IOUS) characteristics of NELM and correlate with tumor biology and prognosis. METHODS: Prospective data on patients who underwent IOUS and surgical intervention for NELM were collected, with images digitally recorded, blindly reviewed, and scored for echogenicity. Association between sonographic appearance, clinicopathologic factors and long-term outcomes was analyzed...
November 2, 2017: HPB: the Official Journal of the International Hepato Pancreato Biliary Association
https://www.readbyqxmd.com/read/29103583/expanded-criteria-for-debulking-of-liver-metastasis-also-apply-to-pancreatic-neuroendocrine-tumors
#18
Rosemary E Morgan, SuEllen J Pommier, Rodney F Pommier
BACKGROUND: Recently, there has been a move toward decreasing the threshold for liver debulking for metastatic carcinoid tumors from 90% to 70%. The debulking threshold and factors that predict outcomes of liver debulking operations specifically among pancreatic neuroendocrine tumors are not well defined. METHODS: Records of patients with pancreatic neuroendocrine tumors undergoing liver debulking with a threshold of 70% from 2006 to 2016 were reviewed. Extrahepatic metastases and positive margins by enucleation were allowed...
November 2, 2017: Surgery
https://www.readbyqxmd.com/read/29102861/an-isolated-metachronous-metastasis-to-the-adrenal-gland-from-a-pancreatic-neuroendocrine-tumor-a-case-report
#19
Yasunaru Sakuma, Naohiro Sata, Kazuhiro Endo, Yoshikazu Yasuda, Shinichiro Yokota, Yoshinori Hosoya, Atsushi Shimizu, Hirofumi Fujii, Daisuke Matsubara, Noriyoshi Fukushima, Shoko Asakawa, Yuuki Kawarai Shimada, Chieko Kawarai Lefor, Alan Kawarai Lefor
INTRODUCTION: Pancreatic neuroendocrine tumors are rare. Treatment includes aggressive local management of the primary lesion and metastases, and systemic somatostatin. This is the first report of an isolated metachronous metastasis to the adrenal gland from a pancreatic neuroendocrine tumor that presented 90 months after the primary tumor. PRESENTATION OF CASE: The patient presented as a 53yo man with a left upper quadrant mass and synchronous metastases to the spleen and liver (pancreatic neuroendocrine tumor T4N0M1, Stage IV), which were resected (CD56-, synaptophysin+, chromogranin+, Ki-67<1%)...
October 19, 2017: International Journal of Surgery Case Reports
https://www.readbyqxmd.com/read/29099418/temozolomide-treatment-of-a-malignant-pheochromocytoma-and-an-unresectable-max-related-paraganglioma
#20
Alfonso M Ferrara, Giuseppe Lombardi, Ardi Pambuku, Domenico Meringolo, Roberta Bertorelle, Margherita Nardin, Francesca Schiavi, Maurizio Iacobone, Giuseppe Opocher, Vittorina Zagonel, Stefania Zovato
Pheochromocytomas (PCCs) and paragangliomas (PGLs) are neuroendocrine tumors with a strong genetic background. The mainstay of treatment for PCC/PGLs is surgery. However, for unresectable lesions, no curative treatment is currently available. Temozolomide (TMZ) has been shown to determine radiological and biochemical response in malignant PCC/PGLs. We report two cases of PCC/PGLs treated with TMZ. Case 1 is a 51-year-old man with local and distant recurrence (liver and bone metastases) of right adrenal PCC...
November 2, 2017: Anti-cancer Drugs
keyword
keyword
77982
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"